Search Results

Business

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, OncologyDr. Beaupre’s extensive clinical research experience bolsters Samumed’s oncology development platform

Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that Dr. Darrin M. Beaupre will join the company as its Chief Medical Officer, Oncology.

December 1, 2020

·

3 min read

Biotech Beach

Michael White, Ph.D. joins Samumed as Chief Scientific Officer

Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced that Dr. Michael White will join the company as its Chief Scientific Officer.

June 1, 2020

·

4 min read

Business

Samumed And United Therapeutics Announce North American License Agreement For Samumed’s IPF Drug Candidate

Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed’s SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).

September 17, 2018

·

4 min read

Biotech Beach

Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting

Samumed, LLC, presented a new clinical safety analysis of lorecivivint, a CLK/DYRK1A inhibitor that modulates the Wnt pathway, in a poster presentation at the 2019 American College of Rheumatology (ACR) Annual Meeting.

November 13, 2019

·

3 min read

Biotech Bay

Samumed Closes on $438 Million in Equity Financing

Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.

August 7, 2018

·

1 min read

Drug Development

Samumed Announces 52-week Phase II Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug

Samumed will be presenting data in three presentations at the 2017 ACR/ARHP Annual Meeting.

October 24, 2017

·

2 min read

Drug Development

Samumed Doses First Patient in Phase I Trial of SM04690 for Treatment of Degenerative Disc Disease

Samumed, today announced the dosing of the first degenerative disc disease patient in its Phase 1 trial of SM04690, a small molecule Wnt pathway inhibitor formulated as an intradiscal injection.

December 18, 2017

·

2 min read

Drug Development

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

X-ray results and pain and function responses highlight the potential of lorecivivint as a first-in-class drug for the treatment of knee osteoarthritis

May 22, 2020

·

4 min read

Biotech Beach

Samumed’s Osteoarthritis Research Selected For An Oral Presentation At A Gordon Research Conference

August 2, 2017

·

1 min read

Drug Development

Samumed Initiates Phase Ib Trial of SM04755 for Treatment of Psoriasis

Top-line data is expected by Q2 2018.

October 31, 2017

·

2 min read